Evidence map›Paper›PMID 38984140›Full record

ArticleFrontiers in ophthalmology2024

Elevated tumor necrosis factor alpha and vascular endothelial growth factor in intermediate age-related macular degeneration and geographic atrophy.

Vivian Rajeswaren, Brandie D Wagner, Jennifer L Patnaik, Naresh Mandava, Marc T Mathias, Niranjan Manoharan, Talisa E de Carlo Forest, Ramya Gnanaraj, Anne M Lynch, Alan G Palestine and 1 more

Abstract read
In one paragraph

Article in Frontiers in ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Vivian RajeswarenDepartment of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, United States.
Brandie D WagnerDepartment of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, United States.
Jennifer L PatnaikDepartment of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, United States.
Naresh MandavaDepartment of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, United States.
Marc T MathiasDepartment of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, United States.
Niranjan ManoharanDepartment of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, United States.
Talisa E de Carlo ForestDepartment of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, United States.
Ramya GnanarajDepartment of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, United States.
Anne M LynchDepartment of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, United States.
Alan G PalestineDepartment of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, United States.
University of Colorado Retina Research Group

Funding

Biomarkers of Systemic Inflammation in Intermediate Age-Related Macular DegenerationR01EY032456 · NEI · UNIVERSITY OF COLORADO DENVER · PI LYNCH, ANNE M. · 2021 to 2024
$1.6M
NEI NIH HHS R01 EY032456
6 · The paper itself

Abstract

Introduction: Tumor necrosis factor alpha (TNF-α) is an inflammatory cytokine implicated in pathological changes to the retinal pigment epithelium that are similar to changes in geographic atrophy (GA), an advanced form of age related macular degeneration (AMD). TNF-α also modulates expression of other cytokines including vascular endothelial growth factor (VEGF), leading to choroidal atrophy in models of AMD. The purpose of this study was to investigate systemic TNF-α and VEGF in patients with GA and intermediate AMD (iAMD) compared to controls without AMD. Methods: We examined plasma levels of TNF-α and VEGF in patients with GA, iAMD, and controls without AMD from the University of Colorado AMD registry (2014 to 2021). Cases and controls were characterized by multimodal imaging. TNF-α and VEGF were measured via multiplex immunoassay and data were analyzed using a non-parametric rank based linear regression model fit to plasma biomarkers. Results: There were 97 GA, 199 iAMD patients and 139 controls. TNF-α was significantly increased in GA (Median:9.9pg/ml, IQR:7.3-11.8) compared to iAMD (Median:7.4, IQR:5.3-9.1) and in both GA and iAMD compared to controls (Median:6.4, IQR:5.3-7.8), p<0.01 for all comparisons. VEGF was significantly increased in iAMD (Median:8.9, IQR:4.8-14.3) compared to controls (Median:7.7, IQR:4.6-11.1), p<0.01. There was a significant positive correlation between TNF-α and VEGF in GA (0.46, p<0.01), and iAMD (0.20, p=0.01) with no significant interaction between TNF-α and VEGF in any group. Discussion: These findings suggest TNF-α and VEGF may contribute to systemic inflammatory processes associated with iAMD and GA. TNF-α and VEGF may function as systemic biomarkers for disease development.

Indexed as

age-related macular degenerationgeographic atrophyintermediate age related macular degenerationtumor necrosis factor alphavascular endothelial growth factor

Identifiers

PMID38984140
PMCPMC11182128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.